
Summary: The U.S. has imposed 100% tariffs on branded and patented drug imports effective October 1, 2025. Although generic drugs remain exempt from these tariffs, the announcement marks a drastic change for pharmaceutical trade which has remained unrestricted for a long time. For Indian pharmaceutical companies supplying nearly half of all generic medicines consumed in the U.S., this development requires them to reassess their market strategies, compliance frameworks, and long-term supply chain planning to navigate an increasingly complex geopolitical environment.Continue Reading Trump’s Tariffs on Pharmaceutical Industry: What Indian Companies Should Know




![Judicial Interplay with Legislation: Analysing the Insolvency and Bankruptcy (Amendment) Bill, 2025 [Part I]](https://disputeresolution.cyrilamarchandblogs.com/wp-content/uploads/sites/894/2025/10/Blog-Image-656x375.png)



